Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CTOR
CTOR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CTOR News
Citius Pharmaceuticals Rated Highly by Wall Street Analysts
May 24 2026
Yahoo Finance
Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026
May 19 2026
NASDAQ.COM
Citius Oncology Reports Q2 2026 Financial Results and Business Update
May 15 2026
PRnewswire
Citius Pharma Reports $5.6 Million Net Revenue in H1 2026
May 15 2026
PRnewswire
Citius Pharma Reports Q2 2026 Financial Results and Business Update
May 15 2026
Newsfilter
Citius Oncology Secures $25 Million Credit Facility for LYMPHIR Commercialization
May 06 2026
PRnewswire
Citius Oncology Secures $25 Million Credit Facility for LYMPHIR Commercialization
May 06 2026
Newsfilter
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma Treatment
Mar 31 2026
PRnewswire
Citius Oncology Launches LYMPHIR, Advancing Cancer Treatment
Mar 31 2026
Newsfilter
LYMPHIR Shows Promise in Gynecologic Cancer Treatment
Mar 10 2026
PRnewswire
Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL
Mar 04 2026
PRnewswire
Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL
Mar 04 2026
Newsfilter
Citius Pharmaceuticals Reports $3.9 Million Revenue in Q1 2026
Feb 13 2026
PRnewswire
Citius Oncology Reports $3.9 Million in Initial Sales Revenue
Feb 13 2026
PRnewswire
Oncolytics Biotech Inc. Reports 33% Response Rate for Pelareorep in Colorectal Cancer
Jan 07 2026
Newsfilter
Oncolytics Biotech's Immunotherapy Shows Significant Improvement in Cancer Treatment Outcomes
Jan 07 2026
PRnewswire
Show More News
